Clinical trials: T-Cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of…
- Trial name
- BELINDA (NCT03570892)
- Testing
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Peripheral T-Cell Lymphoma
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Phase II study designed to investigate antitumor activity in terms of objective response rate (ORR) of tipifarnib subjects with advanced Peripheral T-Cell Lymphoma (PTCL).
- Trial name
- PTCL (NCT02464228)
- Testing
- Tipifarnib
- Where
- 13 sites in United States, South Korea and 1 more
- Volunteers
- 65 people
- Sponsor
- Kura Oncology, Inc.
Lymphoma, B-Cell, Relapse/Recurrence
Dual Target CAR-T Cells in B-cell Lymphoma
Prospectively evaluate the safety and effectiveness of CD19/CD20 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell lymphoma .
- Conditions
- Lymphoma, B-Cell, Relapse/Recurrence, Refractory Lymphoma, Dual-target CAR-T Cells
- Trial name
- CAR-T (NCT04723914)
- Testing
- dual target CAR-T cell therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- YuLi
B Cell Leukemias, B Cell Lymphomas
CD22 Redirected Autologous T Cells for ALL
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in…
- Trial name
- NCT02650414
- Testing
- Cohort 1, Cohorts 2, Cohort 3
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pennsylvania
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
- Trial name
- NCT00006345
- Testing
- denileukin diftitox, dexamethasone
- Where
- 11 sites in United States
- Sponsor
- Ligand Pharmaceuticals
Lymphoma
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1)
Part I evaluates the safety, tolerability and pharmacokinetics (PK) of vorinostat in Japanese patients with relapsed or refractory CTCL. Part II evaluates the safety of vorinostat in Japanese pts.
- Trial name
- NCT00771472
- Testing
- vorinostat
- Volunteers
- 10 people
- Sponsor
- Merck Sharp & Dohme LLC
NK T-Cell Lymphoma
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens.
- Trial name
- NCT07457177
- Testing
- Golidocitinib + Pegaspargase + Anti-PD-1 mAb
- Volunteers
- 40 people
- Sponsor
- LIANG WANG
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
This phase II trial studies how well pembrolizumab and interferon gamma-1b work in treating patients with stage IB-IVB mycosis fungoides and Sezary syndrome that has come back (relapsed) or has not responded to previous treatment…
- Conditions
- Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, Recurrent Mycosis Fungoides and Sezary Syndrome
- Trial name
- NCT03063632
- Testing
- Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
B-Cell Acute Lymphoblastic Leukemia, Adult
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
The purpose of this clinical trial is to learn if autologous bedside CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults.
- Trial name
- NCT07277504
- Testing
- CD19 CAR T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The General Hospital of Western Theater Command
Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory ALCL.
- Trial name
- NCT00866047
- Testing
- brentuximab vedotin
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 58 people
- Sponsor
- Seagen Inc.
Refractory Cutaneous T-cell Lymphoma
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
- Trial name
- NCT01007448
- Testing
- Bexarotene
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- Bausch Health Americas, Inc.
Cytokine Release Syndrome, ICANS
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor…
- Conditions
- Cytokine Release Syndrome, ICANS, Lymphoma, Non-Hodgkin, Multiple Myeloma
- Trial name
- NCT04975555
- Testing
- Siltuximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Alabama at Birmingham
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia.
- Conditions
- B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05281809
- Testing
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- John Lister
Peripheral T-Cell Lymphoma
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma
The standard treatment for PTCL is CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy.
- Trial name
- NCT00337987
- Testing
- Ontak, CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Yale University
Refractory or Relapsed Non-Hodgkin's Lymphoma
Radiomics and Metabolomics in the Follow-up of CAR T-cells for Refractory or Relapsed Non-Hodgkin's Lymphoma
This is an interventionnal pilot study to investigate whether 18FDG radiomics or serum metabolomic signatures could be predictive or prognostic factors in the follow-up of patients receiving CAR T-cell therapy for refractory…
- Trial name
- CART-Omic (NCT05422521)
- Testing
- blood samples and 18FDG PET-CT exams
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
T-cell Lymphoma
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
T-cell Non-Hodgkin's lymphomas are a group of cancers that are usually treated with chemotherapy, radiation therapy, or occasionally surgery. T-cell lymphomas are relatively uncommon and therefore not well studied.
- Trial name
- NCT00322985
- Testing
- Lenalidomide
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- AHS Cancer Control Alberta
Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF)
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL
Objectives of this clinical trial are to evaluate the safety, tolerability, pharmacokinetics and potential efficacy of the investigational drug, cobomarsen (MRG-106), in patients diagnosed with certain lymphomas and leukemias…
- Conditions
- Cutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides (MF), Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma (DLBCL), ABC Subtype
- Trial name
- NCT02580552
- Testing
- Cobomarsen
- Where
- 19 sites in United States
- Volunteers
- 66 people
- Sponsor
- miRagen Therapeutics, Inc.
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
The purpose of this study is to estimate the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) regimen and characterize the pharmacokinetics (PK) of brigatinib monotherapy (film-coated tablets and age-appropriate…
- Conditions
- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
- Trial name
- NCT04260009
- Testing
- Brigatinib, Brigatinib AAF
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.